Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Screen on your Watchlists and Portfolios with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Progenics Pharmaceuticals (PGNX)

Progenics Pharmaceuticals (PGNX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 355,048
  • Shares Outstanding, K 86,597
  • Annual Sales, $ 34,990 K
  • Annual Income, $ -68,550 K
  • 60-Month Beta 1.89
  • Price/Sales 11.20
  • Price/Cash Flow N/A
  • Price/Book 11.60
Trade PGNX with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -0.77
  • Most Recent Earnings N/A on N/A
  • Latest Earnings Date 08/14/20
  • Annual Dividend & Yield 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/20
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year -0.23
  • Growth Rate Est. (year over year) +434,447.83%

Price Performance

See More
Period Period Low Period High Performance
1-Month
3.72 +10.22%
on 05/20/20
4.83 -15.12%
on 06/08/20
+0.47 (+12.95%)
since 05/19/20
3-Month
2.05 +100.00%
on 03/20/20
4.83 -15.12%
on 06/08/20
+1.99 (+94.31%)
since 03/19/20
52-Week
1.89 +116.93%
on 03/19/20
6.37 -35.64%
on 12/23/19
-0.78 (-15.98%)
since 06/19/19

Most Recent Stories

More News
Lantheus Completes Merger with Progenics

Lantheus Holdings, Inc. (the “Company”) (NASDAQ: LNTH), the parent company of Lantheus Medical Imaging, Inc. (“LMI”), a global leader in the development, manufacture and commercialization of innovative...

LNTH : 62.33 (+1.38%)
PGNX : 4.10 (-9.39%)
Progenics Stockholders Approve Merger with Lantheus

NEW YORK, June 16, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq: PGNX) (“Progenics”), an oncology company developing innovative medicines and artificial intelligence to find,...

PGNX : 4.10 (-9.39%)
Lantheus Stockholders Approve Share Issuance For Merger with Progenics

Lantheus Holdings, Inc. (NASDAQ: LNTH) (“Lantheus” or the “Company”), parent company of Lantheus Medical Imaging, Inc. (“LMI”), a leader in the development, manufacture and commercialization...

LNTH : 62.33 (+1.38%)
PGNX : 4.10 (-9.39%)
Progenics to Present Results from the Phase 3 CONDOR Trial of PyL™ (18F-DCFPyL) in Prostate Cancer at the American Society of Clinical Oncology 2020 Virtual Scientific Program

- Met Primary Endpoint with a Correct Localization Rate of 84.8–87.0% - - 63.9% Change in Disease Management Plan Based on PyL Imaging Results - - Planned NDA Submission On Track for Early Third...

PGNX : 4.10 (-9.39%)
Progenics Pharmaceuticals Announces First Quarter 2020 Financial Results and Business Update

NEW YORK, May 07, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX) today announced financial results for the first quarter 2020.

PGNX : 4.10 (-9.39%)
Progenics Pharmaceuticals Sets First Quarter 2020 Financial Results and Business Update Call for May 7

NEW YORK, April 23, 2020 (GLOBE NEWSWIRE) -- Progenics Pharmaceuticals, Inc. (NASDAQ: PGNX), an oncology company developing innovative medicines and artificial intelligence to find, fight and follow...

PGNX : 4.10 (-9.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Sell with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics' first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic...

See More

Key Turning Points

3rd Resistance Point N/A
2nd Resistance Point 5.13
1st Resistance Point 4.61
Last Price 4.10
1st Support Level 3.76
2nd Support Level 3.43
3rd Support Level N/A

See More

52-Week High 6.37
Fibonacci 61.8% 4.66
Fibonacci 50% 4.13
Last Price 4.10
Fibonacci 38.2% 3.60
52-Week Low 1.89

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar